These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38356181)

  • 41. Structural insights into humanization of anti-tissue factor antibody 10H10.
    Teplyakov A; Obmolova G; Malia TJ; Raghunathan G; Martinez C; Fransson J; Edwards W; Connor J; Husovsky M; Beck H; Chi E; Fenton S; Zhou H; Almagro JC; Gilliland GL
    MAbs; 2018; 10(2):269-277. PubMed ID: 29283291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AbDesign: An algorithm for combinatorial backbone design guided by natural conformations and sequences.
    Lapidoth GD; Baran D; Pszolla GM; Norn C; Alon A; Tyka MD; Fleishman SJ
    Proteins; 2015 Aug; 83(8):1385-406. PubMed ID: 25670500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.
    Popkov M; Mage RG; Alexander CB; Thundivalappil S; Barbas CF; Rader C
    J Mol Biol; 2003 Jan; 325(2):325-35. PubMed ID: 12488098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engineering an anti-CD52 antibody for enhanced deamidation stability.
    Qiu H; Wei R; Jaworski J; Boudanova E; Hughes H; VanPatten S; Lund A; Day J; Zhou Y; McSherry T; Pan CQ; Sendak R
    MAbs; 2019 Oct; 11(7):1266-1275. PubMed ID: 31199181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Length-independent structural similarities enrich the antibody CDR canonical class model.
    Nowak J; Baker T; Georges G; Kelm S; Klostermann S; Shi J; Sridharan S; Deane CM
    MAbs; 2016; 8(4):751-60. PubMed ID: 26963563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Computational and artificial intelligence-based methods for antibody development.
    Kim J; McFee M; Fang Q; Abdin O; Kim PM
    Trends Pharmacol Sci; 2023 Mar; 44(3):175-189. PubMed ID: 36669976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition.
    Dondelinger M; Filée P; Sauvage E; Quinting B; Muyldermans S; Galleni M; Vandevenne MS
    Front Immunol; 2018; 9():2278. PubMed ID: 30386328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody Design and Humanization via In Silico Modeling.
    Kurella VB; Gali R
    Methods Mol Biol; 2018; 1827():3-14. PubMed ID: 30196489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
    Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
    J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.
    Ewert S; Honegger A; Plückthun A
    Methods; 2004 Oct; 34(2):184-99. PubMed ID: 15312672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.
    Patel CN; Bauer SP; Davies J; Durbin JD; Shiyanova TL; Zhang K; Tang JX
    J Pharm Sci; 2016 Feb; 105(2):512-518. PubMed ID: 26869414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function.
    Tsuji I; Vang F; Dominguez D; Karwal L; Sanjali A; Livengood JA; Davidson E; Fouch ME; Doranz BJ; Das SC; Dean HJ
    J Virol; 2022 Jun; 96(11):e0007122. PubMed ID: 35575481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.
    Townsend S; Fennell BJ; Apgar JR; Lambert M; McDonnell B; Grant J; Wade J; Franklin E; Foy N; Ní Shúilleabháin D; Fields C; Darmanin-Sheehan A; King A; Paulsen JE; Hickling TP; Tchistiakova L; Cunningham O; Finlay WJ
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15354-9. PubMed ID: 26621728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation.
    Bowers PM; Neben TY; Tomlinson GL; Dalton JL; Altobell L; Zhang X; Macomber JL; Wu BF; Toobian RM; McConnell AD; Verdino P; Chau B; Horlick RA; King DJ
    J Biol Chem; 2013 Mar; 288(11):7688-7696. PubMed ID: 23355464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic classification of CDR-L3 in antibodies: implications of the light chain subtypes and the VL-VH interface.
    Kuroda D; Shirai H; Kobori M; Nakamura H
    Proteins; 2009 Apr; 75(1):139-46. PubMed ID: 18798566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RosettaAntibodyDesign (RAbD): A general framework for computational antibody design.
    Adolf-Bryfogle J; Kalyuzhniy O; Kubitz M; Weitzner BD; Hu X; Adachi Y; Schief WR; Dunbrack RL
    PLoS Comput Biol; 2018 Apr; 14(4):e1006112. PubMed ID: 29702641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody CDR loops as ensembles in solution vs. canonical clusters from X-ray structures.
    Fernández-Quintero ML; Heiss MC; Pomarici ND; Math BA; Liedl KR
    MAbs; 2020; 12(1):1744328. PubMed ID: 32264741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
    Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
    MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.
    Harding FA; Stickler MM; Razo J; DuBridge RB
    MAbs; 2010; 2(3):256-65. PubMed ID: 20400861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new clustering of antibody CDR loop conformations.
    North B; Lehmann A; Dunbrack RL
    J Mol Biol; 2011 Feb; 406(2):228-56. PubMed ID: 21035459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.